Abbott Laboratories Stock News

Abbott stock surged early Friday after a jury decided baby formula from Abbott and Mead Johnson are not responsible for a boy's disease. The post Abbott Surges After Avoiding Another 'Eye-Popping' Verdict In Baby Formula Trial appeared first on Investor's Business Daily.

Abbott Laboratories shares rose nearly 5% before the bell on Friday, after a jury cleared the company and a Reckitt unit of liability in a lawsuit over their premature baby formulas' risks.

A court in St. Louis, Missouri ruled in favor of Abbott Laboratories and Reckitt Benckiser over claims their specialized baby formula caused users to develop a bowel disease called NEC

Abbott and Reckitt unit Mead Johnson are not responsible for a young boy's debilitating intestinal disease, a jury found on Thursday in a lawsuit accusing them of failing to warn of their premature baby formulas' risks, a victory for the two companies following large losses in similar trials.

A lawyer for a Missouri mother on Wednesday asked a jury to make Abbott and Reckitt's Mead Johnson pay a total of more than $6 billion in the latest trial over claims that the companies' formulas for premature babies caused a severe intestinal illness.

Investors looking for health-related buy-and-hold stocks must look no further than this list. The stocks on this list are market leaders in healthcare, producing sustainable growth with healthy balance sheets, impressive value, and broad market support.

The ProShares S&P 500 Dividend Aristocrats ETF went on a great run during Q3, gaining 11.6% during the quarter. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 39 months of tracking these strategies, all 3 strategies are generating a CAGR superior to NOBL while also offering a higher dividend yield.

PALO ALTO, Calif.--(BUSINESS WIRE)--Tidepool and Abbott collaborate to integrate data, expand patient choice, and improve clinical workflows.